ResMed Inc. 10-Q Summary: Quarter Ended September 30, 2004
Business Context and Reporting Period
This filing covers the quarterly period ended September 30, 2004. ResMed Inc. is a leading developer, manufacturer, and marketer of medical equipment for the diagnosis, treatment, and management of sleep-disordered breathing, primarily obstructive sleep apnea. The company operates manufacturing facilities in Australia, Germany, and the United States, with major distribution sites globally.
Key Financial Metrics
| Metric | Q3 2004 | Q3 2003 |
|---|---|---|
| Net Revenue | $87.7 million | $72.9 million |
| Gross Profit | $56.4 million | $47.2 million |
| Gross Margin | 64.3% | 64.7% |
| Net Income | $13.9 million | $12.2 million |
| Diluted EPS | $0.39 | $0.35 |
| Operating Cash Flow | $16.6 million | $12.6 million |
| Cash & Equivalents | $141.6 million | $104.7 million |
| Long-Term Debt | $113.3 million | $113.3 million |
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 20% year-over-year, driven by higher unit sales of flow generators and masks. North and Latin America revenue grew 32%, while international markets grew 10%.
- Margin Pressure: Gross margin declined slightly to 64% from 65%. This was primarily due to a stronger Australian dollar increasing manufacturing costs, partially offset by a favorable product mix.
- Restructuring Costs: The company incurred $2.0 million in restructuring expenses related to integrating ResMed Germany and MAP operations. This is a one-time charge not present in the prior year.
- Expense Increases: Selling, general, and administrative (SG&A) expenses rose 20% to $26.7 million, and R&D expenses increased 13% to $6.8 million, largely due to personnel increases and currency impacts.
Outlook, Risks, and Management Commentary
- Restructuring Outlook: Total restructuring expenses are estimated at $4.5 million, with the balance expected to be incurred during fiscal year 2005.
- Capital Projects: The company is constructing a new sleep center, R&D, and office facilities in Sydney, Australia. Estimated additional building costs are approximately $54 million, with completion expected in late 2004 to late 2006.
- Share Repurchases: ResMed repurchased 241,090 shares for $11.0 million during the quarter. Since the program's inception, 1.13 million shares have been repurchased for $41.4 million.
- Key Risks:
- Currency Fluctuation: Significant exposure to the Australian dollar and Euro, which impacts both revenue translation and manufacturing costs.
- Regulatory & Reimbursement: Dependence on third-party payer reimbursement and FDA approvals for new products.
- Supply Chain: Reliance on single-source suppliers for certain components.
- Tax Audit: An ongoing tax audit of a German subsidiary for years 1996-1998; management believes no additional provision is currently necessary.
Investor Verification Checklist
- Verify the impact of the Australian dollar exchange rate on future gross margins.
- Monitor the progress and cost overruns of the $54 million Sydney campus construction project.
- Track the resolution of the German tax audit and potential liability exposure.
- Assess the integration success of the German operations (ResMed Germany and MAP) and the realization of cost synergies.
- Review the sustainability of the 20% revenue growth rate in the context of competitive market dynamics.